Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults

被引:53
作者
Halperin, SA
Smith, B
Russell, M
Scheifele, D
Mills, E
Hasselback, P
Pim, C
Meekison, W
Parker, R
Lavigne, P
Barreto, L
机构
[1] IWK Grace Hlth Ctr, Halifax, NS B3J 3G9, Canada
[2] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada
[3] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada
[4] Dalhousie Univ, Dept Math & Stat, Halifax, NS, Canada
[5] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada
[6] Univ Lethbridge, Sch Hlth Sci, Lethbridge, AB T1K 3M4, Canada
[7] Chinook Hlth Reg, Lethbridge, AB, Canada
[8] Calgary Reg Hlth Author, Calgary, AB, Canada
[9] British Columbia Childrens Hosp, Vaccine Evaluat Ctr, Vancouver, BC V6H 3V4, Canada
[10] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[11] Simon Fraser Hlth Unit, Fraser Valley, BC, Canada
[12] Pasteur Merieux Connaught Canada, Toronto, ON, Canada
关键词
acellular pertussis vaccine; adult and adolescent immunization; Bordetella peritussis; safety; immunogenicity;
D O I
10.1097/00006454-200004000-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Pertussis is increasingly recognized as an important cause of cough illness inn adolescents and adults, Purpose. To evaluate the safety and antibody response to a single dose of an adult formulation of a five component (pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae 2 and 3) acellular pertussis vaccine (aP) combined with diphtheria and tetanus toxoids (TdaP) and inactivated poliovirus vaccine (TdaP-IPV) in adolescents and adults and to assess the response to a second dose of the acellular pertussis vaccine in a subset of the adults, Population and setting. The study addressed 1207 healthy participants (736 adults and 466 adolescents) recruited in five Canadian communities, Study design, in a randomized, observer-blind, controlled clinical trial, adult participants received Td followed at a separate visit by aP, TdaP followed by IPV or TdaP-IPV; adolescents received Td-IPV followed at a separate visit by aP or TdaP-IPV. A subgroup of adults was given a booster of aP 1 month after TdaP. Outcome measures. Antibody titers measured before and 1 month after each immunization; adverse events enumerated at 24 h, 72 h and 8 to 10 days. Results. The aP vaccine given by itself was associated with adverse events less frequently than were Td, Td-IPV, TdaP or TdaP-IPV vaccines, hut reaction rates did not differ significantly among the latter products, The antibody response against Bordetella pertussis antigens was vigorous in all groups, although adults given the TdaP-IPV vaccine had newer antibody titers against filamentous hemagglutinin, pertactin, diphtheria and tetanus antibodies than those given TdaP vaccine, Similarly adolescents given TdaP-IPV had lower antibody titers against pertussis toxin, filamentous hemaagglutinin, fimbriae and agglutinins than those given Td-IPV and aP alone. A second dose of acellular pertussis vaccine was not associated with increased adverse events in adults but elicited increased antibody titers over that achieved by a single dose only against pertussis toxin, Conclusions, This adult formulation five component aP vaccine given as TdaP-IPV is safe and immunogenic in adolescents and adults and is a candidate vaccine for adolescent and adult immunization programs.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 39 条
[1]   PERTUSSIS IN ADULTS [J].
AOYAMA, T ;
TAKEUCHI, Y ;
GOTO, A ;
IWAI, H ;
MURASE, Y ;
IWATA, T .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1992, 146 (02) :163-166
[2]  
Aoyama Tatsuo, 1995, Acta Paediatrica Japonica, V37, P321
[3]   COMPARISON OF VALUES OF ANTIBODY TO BORDETELLA-PERTUSSIS ANTIGENS IN YOUNG GERMAN AND AMERICAN MEN [J].
CHERRY, JD ;
BEER, T ;
CHARTRAND, SA ;
DEVILLE, J ;
BEER, E ;
OLSEN, MA ;
CHRISTENSON, PD ;
MOORE, CV ;
STEHR, K .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1271-1274
[4]  
CHERRY JD, 1989, WESTERN J MED, V150, P319
[5]   FREQUENCY OF UNRECOGNIZED BORDETELLA-PERTUSSIS INFECTIONS IN ADULTS [J].
DEVILLE, JG ;
CHERRY, JD ;
CHRISTENSON, PD ;
PINEDA, E ;
LEACH, CT ;
KUHLS, TL ;
VIKER, S .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (03) :639-642
[6]   ADULT IMMUNIZATION WITH ACELLULAR PERTUSSIS-VACCINE [J].
EDWARDS, KM ;
DECKER, MD ;
GRAHAM, BS ;
MEZZATESTA, J ;
SCOTT, J ;
HACKELL, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (01) :53-56
[7]   CONTROLLED-STUDY OF A NEW 5-COMPONENT ACELLULAR PERTUSSIS-VACCINE IN ADULTS AND YOUNG-CHILDREN [J].
ENGLUND, JA ;
GLEZEN, WP ;
BARRETO, L .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1436-1441
[8]   EPIDEMIOLOGIC FEATURES OF PERTUSSIS IN THE UNITED-STATES, 1980-1989 [J].
FARIZO, KM ;
COCHI, SL ;
ZELL, ER ;
BRINK, EW ;
WASSILAK, SG ;
PATRIARCA, PA .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (03) :708-719
[9]   ACELLULAR PERTUSSIS-VACCINE IN ADULTS - ADVERSE REACTIONS AND IMMUNE-RESPONSE [J].
GRANSTROM, M ;
THOREN, M ;
BLENNOW, M ;
TIRU, M ;
SATO, Y .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (01) :18-21
[10]   A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine [J].
Gustafsson, L ;
Hallander, HO ;
Olin, P ;
Reizenstein, E ;
Storsaeter, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06) :349-355